Precigen, Inc. (PGEN) stock
PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.16−0.11 (-2.58%)
Close on Nov 19, 2026Market cap $1.49BP/E –Yield –
Precigen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Precigen's operating income for the twelve months ending Dec 31, 2020 was -$86.60M. For fiscal 2025 it was -$110.51M. The highest annual figure on record is -$58.02M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$110.51M | – |
| FY2024 | Dec 31, 2024 | -$135.03M | – |
| FY2023 | Dec 31, 2023 | -$99.76M | – |
| FY2018 | Dec 31, 2018 | -$505.61M | – |
| FY2017 | Dec 31, 2017 | -$137.89M | – |
| FY2016 | Dec 31, 2016 | -$125.17M | – |
| FY2015 | Dec 31, 2015 | -$146.86M | – |
| FY2014 | Dec 31, 2014 | -$69.96M | – |
| FY2013 | Dec 31, 2013 | -$58.02M | – |
| FY2012 | Dec 31, 2012 | -$75.16M | – |
| FY2011 | Dec 31, 2011 | -$82.43M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.99M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.60M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.17M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.60M | – |
| Q4 FY2019 | Dec 31, 2019 | -$68.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$34.70M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.51M | – |
| Q1 FY2019 | Mar 31, 2019 | -$41.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$268.12M | – |
| Q3 FY2018 | Sep 30, 2018 | -$58.33M | – |
| Q2 FY2018 | Jun 30, 2018 | -$34.81M | – |
| Q1 FY2018 | Mar 31, 2018 | -$42.24M | – |
| Q4 FY2017 | Dec 31, 2017 | -$26.49M | – |
| Q3 FY2017 | Sep 30, 2017 | -$44.75M | – |
| Q2 FY2017 | Jun 30, 2017 | -$35.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$31.38M | – |
| Q4 FY2016 | Dec 31, 2016 | -$32.59M | – |
| Q3 FY2016 | Sep 30, 2016 | -$28.82M | – |
See a number that looks wrong?